Literature DB >> 3631471

Gastric emptying and small bowel transit times in volunteers after intravenous morphine and nalbuphine.

H Yukioka, M Rosen, K T Evans, K G Leach, M W Hayward, G S Saggu.   

Abstract

Gastric emptying half-times and small intestinal transit times were measured in a double-blind crossover study of 17 volunteers who received an intravenous injection of nalbuphine (5 or 10 mg), morphine (5 mg) or placebo. Both times were monitored using a gamma camera after a radioactive test meal and gastric emptying half-time was calculated. Small intestinal transit time was measured by the appearance of radioactivity in the caecum and also of hydrogen in end tidal air. Gastric emptying was prolonged over placebo by nalbuphine 10 mg, which had more effect than nalbuphine 5 mg or morphine 5 mg; morphine 5 mg had less effect than nalbuphine 5 mg. Small intestinal transit time was prolonged over placebo by nalbuphine 10 mg more than by nalbuphine 5 mg or morphine 5 mg, which had approximately equal effects. In these respects, the potency ratio of nalbuphine appears roughly equivalent to morphine. Small intestinal transit times measured by end tidal hydrogen concentration and gamma camera showed close agreement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631471     DOI: 10.1111/j.1365-2044.1987.tb05314.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  10 in total

Review 1.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

2.  Cisapride reduces postoperative gastrocaecal transit time after cardiac surgery in children.

Authors:  L Bindl; S Buderus; M Ramirez; P Kirchhoff; M J Lentze
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

3.  Potentiating effect of morphine on oral Salmonella enterica serovar Typhimurium infection is μ-opioid receptor-dependent.

Authors:  Jessica M Breslow; Pu Feng; Joseph J Meissler; John E Pintar; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  Microb Pathog       Date:  2010-08-03       Impact factor: 3.738

Review 4.  Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Authors:  J M Greiff; D Rowbotham
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 5.  Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections.

Authors:  Sabita Roy; Jana Ninkovic; Santanu Banerjee; Richard Gene Charboneau; Subhas Das; Raini Dutta; Varvara A Kirchner; Lisa Koodie; Jing Ma; Jingjing Meng; Roderick A Barke
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-26       Impact factor: 4.147

Review 6.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

7.  [Constipation after tilidine/naloxone and tramadol in comparison to codeine. A dose response study in human volunteers].

Authors:  E Freye; B Rosenkranz; B Neruda
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

8.  Effects of Nalbuphine on Gastrointestinal Function in Post-Operative Critical Ill Patients Admitted to the ICU: A Multicenter Randomized Controlled Trial.

Authors:  Yun Yan; Chong Lei; Binxiao Su; Enxia Dong; Guangming Wang; Bin Li; Xinyu Li; Aiguang Li; Guifen Gan; Yu Chen; Xijing Zhang
Journal:  Front Med (Lausanne)       Date:  2022-02-16

Review 9.  Tumor-related dysmotility: gastrointestinal dysmotility syndromes associated with tumors.

Authors:  J K DiBaise; E M Quigley
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.487

10.  Changes in bowel sounds of inpatients undergoing general anesthesia.

Authors:  Guojing Wang; Mingjun Wang; Hongyun Liu; Suping Zhao; Lu Liu; Weidong Wang
Journal:  Biomed Eng Online       Date:  2020-07-30       Impact factor: 2.819

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.